Navigation Links
Combination therapy reduced HER2-positive breast cancers
Date:12/10/2010

SAN ANTONIO A combination of lapatinib, trastuzumab and paclitaxel significantly improved tumor response rates than either agent alone among patients with HER2-positive breast cancers, according to data presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12. Full results were presented at the symposium during a press briefing on Dec. 10, 2010, at 8:00 a.m. CT.

Reporters who cannot attend in person can participate using the following call-in information:

  • U.S. and Canada: (888) 282-7404
  • International: (706) 679-5207
  • Access Code: 25346432

Lead researcher Jos Baselga, M.D., Ph.D., chief of the division of hematology and oncology and associate director of the Massachusetts General Hospital Cancer Center, said early data indicate a 50 percent rate of pathological complete remission compared with 20 percent for either agent alone.

"This study suggests that a dual blockade against HER2 is an efficient way to target HER2-positive breast tumors and that lapatinib adds to trastuzumab. While further research is ongoing, our results indicate that we are on the right track to improve the therapy of HER2-positive disease," said Baselga, who is also a founding editor-in-chief of the AACR's newest journal Cancer Discovery, along with Lewis C. Cantley, Ph.D.

These results are from the NeoALTTO Trial, an international, multicenter, randomized study comparing the efficacy of lapatinib plus paclitaxel vs. trastuzumab plus paclitaxel vs. a combination of all three agents as neoadjuvant chemotherapy among 455 patients with HER2-positive breast cancer.

"It has been suggested in basic science research and smaller clinical trials that the combination of these therapies would be more effective than either alone, but this is the first time it has been shown in a large clinical trial setting," said Baselga.

At the symposium, Baselga presented the primary outcome of tu
'/>"/>

Contact: Jeremy Moore
jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Page: 1 2

Related biology news :

1. Pertuzumab and trastuzumab combination improved efficacy for women with HER2-positive breast cancer
2. Novocure reports data showing TTF therapy in combination with chemotherapy has the potential to increase overall survival for patients with advanced non-small cell lung cancer
3. Grape news: New treatment combination safe alternative to sulfur dioxide
4. Study: Grass, fungus combination affects ecology
5. Investigators identify cleat/natural grass combination may be less likely to result in ACL injury
6. Diabetes drug kills cancer stem cells in combination treatment in mice
7. Old stain in a new combination
8. Phase III study compared neoadjuvant therapy with lapatinib or trastuzumab for early breast cancer
9. Early safety results promising for Phase I/II trial of gene therapy treatment of hemophilia B
10. Virginia Tech engineers introduce thermotherapy as a chemotherapy alternative
11. Never-smokers fare far better than smokers after radiation therapy for head and neck cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2014)... Dec. 9, 2014  Valencell, a leader in performance ... a staggering demand from its licensees for highly accurate, ... is not solely coming from fitness and health sectors, ... "A wearable is only as useful as the ... the ultimate driver in long-term mass consumer adoption of ...
(Date:12/10/2014)... 2014 CIE San Diego has launched an ... connective tissue that enhances care coordination among social service ... client-level information; earned a second $1 million grant from ... seniors aging in community and; will be recognized as ... th 4-6p. CIE San Diego today ...
(Date:12/10/2014)... , December 9, 2014 ... ITN,s BCARD Platform   ... enterprise meeting scheduling solutions for business-to-business (B2B) events, ... world leader in mobile near-field communication (NFC), Bluetooth ...      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
... The GARBAN project, drawn up by Navarre University, will ... and hepatitis. , The School of Engineering at Navarre ... in Gipuzkoa (CEIT) have launched an advanced biochemical analysis ... diseases, accelerate their diagnosis and identify new therapeutic targets ...
... long time that only 2% -- 3% of human DNA ... -- often referred to as junk DNA -- consists of ... DNA, and then reinserted into a new spot in the ... retroelements. Retroviruses can insinuate themselves into the host's DNA in ...
... magnetic "nanoparticles" to DNA and then cut these "DNA ... self-assembling devices for future computers. , Findings are detailed ... Journal of the American Chemical Society. The paper was ... Albena Ivanisevic, an assistant professor of biomedical engineering and ...
Cached Biology News:Analysis Of Human Genome To Predict The Development Of Illnesses 2Chimp genome reveals a retroviral invasion 2Chimp genome reveals a retroviral invasion 3Purdue researchers use enzyme to clip 'DNA wires' 2Purdue researchers use enzyme to clip 'DNA wires' 3
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
(Date:12/19/2014)... Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... that they have been acquired by Roche (SIX: RO, ... privately held company that provides a big data platform ... (NGS) data for the academic and translational research markets. ... and will continue to focus on development of their ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... have an advantage in the media. A new study ... published in the journal of Israel,s National Security College, ... this arena too. , "Information warfare" plays ... sometimes more so than conventional weapons. Therefore, the information ...
... discovered a way to use an ancient life form to ... systems that may be surprisingly simple to build compared to ... tiny, single-celled marine life forms have existed for at least ... the life in the oceans, but they also have rigid ...
... Inc. (Nasdaq: ANDS ) announced today that ... Thursday, April 23, 2009, after the U.S. financial markets ... Thursday, April 23, 2009 at 5:00 p.m. Eastern Daylight ... and highlights and to provide an update on its ...
Cached Biology Technology:Information warfare in the 21st century: Ideas are sometimes stronger than bombs 2Ancient diatoms lead to new technology for solar energy 2Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results 2
Request Info...
...
... potent inhibition of RNase A-type ribonucleases Product ... of nonhuman origin that binds noncovalently and ... A, B, and C). It does not ... U2, or CL3. QIAGEN RNase Inhibitor inhibits ...
Request Info...
Biology Products: